| ABBV |
Report |
Q2 2026 Skyrizi revenue |
BEAT |
pred ~$5.58B vs. cons $5.49B |
MEDIUM |
| ABBV |
Report |
Q2 2026 Rinvoq revenue |
BEAT |
pred ~$2.52B vs. cons $2.47B |
MEDIUM |
| ABBV |
Report |
Q2 2026 total net revenue |
IN-LINE |
pred ~$16.89B vs. cons $16.77B |
MEDIUM |
| ABBV |
Guide |
Full-year net revenue |
BETTER |
guide ~$67.8B vs. cons $67.32B (FY 2026) |
MEDIUM |
| ABBV |
Guide |
Full-year adjusted diluted EPS including known IPR&D |
LOWER |
guide ~$14.13 vs. cons $14.18 (FY 2026) |
MEDIUM |
| ABBV |
Guide |
Skyrizi revenue |
BETTER |
guide ~$22.0B vs. cons $21.9B (FY 2026) |
MEDIUM |
| ABBV |
Guide |
Rinvoq revenue |
BETTER |
guide ~$10.4B vs. cons $10.3B (FY 2026) |
MEDIUM |
| ABBV |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.4% |
— |
MEDIUM |
| ABBV |
Return |
5-day cumulative residual |
+1.2% (FADE) |
Skyrizi and Rinvoq beats plus a higher revenue outlook support the initial move, but FY 2026 EPS guidance of ~$14.13 versus $14.18 consensus and roughly $0.46 of expected 2027 Apogee dilution should pull out-period estimates lower, fading part of the day-1 gain. |
MEDIUM |